The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. The primary questions it aims to answer are:

• Does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation?

The improvement of the disease will be assessed through the following parameters:

• liver laboratory tests
• weight loss
• improvement in cholesterol and triglyceride levels. Researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis.

Participants will be randomly assigned to two groups. The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.

Inclusion Criteria:

• Patients seen in outpatient gastroenterology clinics with hepatic steatosis.
• Diagnosed with hepatic steatosis through ultrasound or abdominal CT scan
• Mild to moderate fibrosis as assessed by elastography or FibroScan (F1-F3) or with a Fibrosis-4 (FIB-4) Index less than 3.5.
• Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.

Exclusion Criteria:

• Patients who do not have any hepatic imaging test conducted in the last 5 years.
• Conditions other than hepatic steatosis requiring gastroenterological follow-up.
• Abusive alcohol consumption, defined as weekly intake of > 50 g in women and more than 70 g in men.
• Cognitive or affective disorders limiting the ability to cooperate with study procedures.
• Participation in another clinical trial involving experimental intervention during the period of this trial and/or establishing visit schedules incompatible with this trial.

IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

After publication of main results of the study.

IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.